Mechanisms involved in the inhibition of osteoclast generation by the benzothiophene SERM LY117018

Wiener Klinische Wochenschrift

Volumn 122, Issue 21-22, 2010, Pages 626-632

  Wutzl, Arno ^a   Gruber, Reinhard ^a   Brozek, Wolfgang ^a   Hofbauer, Günter ^b   Lernbass, Isolde ^a   Brosch, Susanne ^a   Pietschmann, Peter ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

LY117018; Osteoclast; Osteoporosis; RANKL; TNF

Indexed keywords

6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; ALKALINE PHOSPHATASE; CD8 ANTIGEN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; BONE MARROW CULTURE; CALVARIA; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME ACTIVITY; FLOW CYTOMETRY; IN VITRO STUDY; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; SPLEEN CELL;

ANIMALS; ANIMALS, NEWBORN; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; OSTEOCLASTS; PYRROLIDINES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; THIOPHENES;

EID: 78651391335     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-010-1469-z     Document Type: Article

References (30)

1. BL Riggs LJ Melton 3rd 1986 Involutional osteoporosis N Engl J Med 314 1676 1686 1:STN:280:DyaL283jtVOntw%3D%3D 10.1056/NEJM198606263142605 3520321
2. LJ Melton 3rd HW Wahner LS Richelson WM O'Fallon BL Riggs 1986 Osteoporosis and the risk of hip fracture Am J Epidemiol 124 254 261 3728441
3. Q Qu PL Harkonen HK Vaananen 1999 Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture J Cell Biochem 15 500 507 10.1002/(SICI)1097-4644(19990615)73:4<500::AID- JCB8>3.0.CO;2-E
4. R Lindsay DM Hart JM Aitken EB MacDonald JB Anderson AC Clarke 1976 Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment Lancet 1 1038 1041 1:STN:280:DyaE287ntlehtQ%3D%3D 10.1016/S0140-6736(76)92217-0 57448
5. 3 on interleukin-6 production and osteoclast-like cell formation in mouse bone marrow primary cultures Endocrinology 138 4567 4571 1:CAS:528:DyaK2sXmslGku7k%3D 10.1210/en.138.11.4567 9348179
6. ES LeBlanc CM Viscoli JB Henrich 1999 Postmenopausal estrogen replacement therapy is associated with adverse breast cancer prognostic indices J Womens Health Gend Based Med 8 815 823 1:STN:280:DyaK1Mvhs1anuw%3D%3D 10.1089/152460999319138 10495262
7. Writing group for the women's health initiative investigators 2002 Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomised controlled trial JAMA 17 321 10.1001/jama.288.3.321
8. R Fuchs-Young AL Glasebrook LL Short MW Draper MK Rippy HW Cole, et al. 1995 Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor Ann NY Acad Sci 761 355 360 1:CAS:528:DyaK2MXptFOmurk%3D 10.1111/j.1749-6632.1995.tb31392.x 7625735
9. NN Yang M Venugopalan S Hardikar A Glasebrook 1996 Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene Science 30 1222 1225 10.1126/science.273.5279.1222
10. B Ettinger DM Black BH Mitlak RK Knickerbocker T Nickelsen HK Genant, et al. 1999 Reduction of vertebral fracture risk in postmenopausal women treated with raloxifene: results from a 3-year randomised clinical trial JAMA 282 637 645 1:CAS:528:DyaK1MXlvVKqurg%3D 10.1001/jama.282.7.637 10517716
11. G Evans H Bryant M Sato RT Turner 1993 Raloxifene is a tissue specific estrogen agonist J Bone Miner Res 8 134
12. C Huber S Collishaw JR Mosley J Reeve BS Noble 2007 Selective estrogen receptor modulator inhibits osteocyte apoptosis during abrupt estrogen withdrawal: implications for bone quality maintenance Calcif Tissue Int 81 139 144 1:CAS:528:DC%2BD2sXosFOgsr0%3D 10.1007/s00223-007-9049-6 17638036
13. C Jochems U Islander A Kallkopf M Lagerquist C Ohlsson H Carlsten 2007 Role of raloxifene as a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis Arthritis Rheum 56 3261 3270 1:CAS:528: DC%2BD2sXht12rtLnJ 10.1002/art.22873 17907171
14. AB Hodsman D Drost LJ Fraher D Holdsworth M Thornton J Hock, et al. 1999 The addition of a raloxifene analog (LY117018) allows for reduced PTH (1-34) dosing during reversal of osteopenia in ovariectomized rats J Bone Miner Res 14 675 679 1:CAS:528:DyaK1MXjtFKrsbk%3D 10.1359/jbmr.1999.14.5.675 10320515
15. C Schiller R Gruber K Redlich GM Ho F Katzgraber M Willheim, et al. 1997 17Beta-estradiol antagonizes effects of 1alpha,25-dihydroxyvitamin D3 on interleukin-6 production and osteoclast-like cell formation in mouse bone marrow primary cultures Endocrinology 138 4567 4571 1:CAS:528:DyaK2sXmslGku7k%3D 10.1210/en.138.11.4567 9348179
16. N Fratzl-Zelman H Horandner E Luegmayr F Varga A Ellinger MP Erlee, et al. 1997 Effects of triiodothyronine on the morphology of cells and matrix, the localization of alkaline phosphatase, and the frequency of apoptosis in long-term cultures of MC3T3-E1 cells Bone 20 225 236 1:CAS:528: DyaK2sXit12qsLk%3D 10.1016/S8756-3282(96)00367-5 9071473
17. JC Huang T Sakata LL Pfleger M Bencsik BP Halloran DD Bikle, et al. 2004 PTH differentially regulates expression of RANKL and OPG J Bone Miner Res 9 235 244
18. M Willheim R Thien K Schrattbauer E Bajna M Holub R Gruber, et al. 1999 Regulatory effects of 1alpha,25-dihydroxyvitamin D3 on the cytokine production of human peripheral blood lymphocytes J Clin Endocrinol Metab 84 3739 3744 1:CAS:528:DyaK1MXms1Ohurg%3D 10.1210/jc.84.10.3739 10523023
19. R Gruber K Czerwenka F Wolf GM Ho M Willheim M Peterlik 1999 Expression of the vitamin D receptor, of estrogen and thyroid hormone receptor alpha- and beta-isoforms, and of the androgen receptor in cultures of native mouse bone marrow and of stromal/osteoblastic cells Bone 24 465 473 1:CAS:528: DyaK1MXjtV2jsrs%3D 10.1016/S8756-3282(99)00017-4 10321906
20. Q Qu PL Harkonen HK Vaananen 1999 Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture J Cell Biochem 73 500 507 1:CAS:528:DyaK1MXjsVOlsbg%3D 10.1002/(SICI)1097- 4644(19990615)73:4<500::AID-JCB8>3.0.CO;2-E 10733344
21. HK Genant T Lang T Fuerst KV Pinette C Zhou D Thiebaud, et al. 2004 Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography Bone 35 1164 1168 1:CAS:528:DC%2BD2cXpslOqtLs%3D 10.1016/j.bone.2004.07.006 15542042
22. A Taranta M Brama A Teti V De luca R Scandurra G Spera, et al. 2002 The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro Bone 30 368 376 1:CAS:528:DC%2BD38Xhtleqsro%3D 10.1016/S8756-3282(01)00685-8 11856644
23. J Yu M Eto K Kozaki M Akishita T Okabe Y Ouchi 2008 Raloxifene analogue LY117018 suppresses oxidative stress-induced endothelial cell apoptosis through activation of ERK1/2 signaling pathway Eur J Pharmacol 28 589 32 36 10.1016/j.ejphar.2008.04.052
24. J Cheung YT Mak S Papaioannou BA Evans I Fogelman G Hampson 2003 Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene J Endocrinol 177 423 433 1:CAS:528:DC%2BD3sXkslCgtbk%3D 10.1677/joe.0.1770423 12773123
25. JS Duke-Cohan H Weinberg R Sharon D Naor 1985 Immunological function in osteoporosis Clin Immunol Immunopathol 35 125 129 1:STN:280:DyaL2M3gt1ertA%3D%3D 10.1016/0090-1229(85)90085-6 3158457
26. KR Rubin M Ballow R Baron RM Greenstein LG Raisz DW Rowe 1988 Malignant osteoporosis and defective immunoregulation J Bone Miner Res 3 509 516 1:STN:280:DyaL1M%2FlvFykug%3D%3D 10.1002/jbmr.5650030506 3195363
27. T Fujita T Matsui Y Nakao S Watanabe 1984 T lymphocyte subsets in osteoporosis. Effect of 1-alpha hydroxyvitamin D3 Miner Electrolyte Metab 10 375 378 1:STN:280:DyaL2M%2FmtVOrug%3D%3D 6334223
28. P Pietschmann J Grisar R Thien M Willheim K Kerschan-Schindl E Preisinger, et al. 2001 Immune phenotype and intracellular cytokine production of peripheral blood mononuclear cells from postmenopausal patients with osteoporotic fractures Exp Gerontol 36 1749 1759 1:CAS:528:DC%2BD3MXnslWqur0%3D 10.1016/S0531-5565(01)00125-5 11672994
29. O Kudo Y Fujikawa I Itonaga A Sabokbar T Torisu NA Athanasou 2002 Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation J Pathol 198 220 227 1:CAS:528:DC%2BD3sXivV2jsrc%3D 10.1002/path.1190 12237882
30. MC Horowitz 1993 Cytokines and estrogen in bone: anti-osteoporotic effects Science 30 626 627 10.1126/science.8480174